Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133503 | 0.98 | S1PR1 (0.56) | S1PR1S1PR3S1PR5MAP4K4PRKCD | |
| SCHEMBL2134091 | 0.93 | S1PR1 (0.62) | S1PR1S1PR3S1PR5MAP4K4PRKCD | |
| SCHEMBL2134240 | 0.92 | S1PR1 (0.63) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2133183 | 0.90 | S1PR1 (0.63) | S1PR1S1PR3S1PR5MAP4K4PRKCD | |
| SCHEMBL2619462 | 0.90 | S1PR1 (0.56) | S1PR1S1PR3S1PR5MAP4K4PRKCD | |
| SCHEMBL2135240 | 0.89 | S1PR1 (0.64) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2134388 | 0.89 | S1PR1 (0.52) | S1PR1S1PR3S1PR5MAP4K4PRKCD | |
| SCHEMBL2134475 | 0.88 | S1PR1 (0.57) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2619463 | 0.88 | S1PR1 (0.46) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2132652 | 0.88 | S1PR1 (0.52) | S1PR1S1PR3S1PR5MAP4K4PRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445892-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| WO-2010148650-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.